Agreements reached under this partnership
Capital and Business Alliance- 1
Subscription for a third-party allotment (first stage: making REMED JAPAN an equity-method affiliate)
- 2
Management Structure
- 3
Right to acquire additional shares (second stage: making REMED JAPAN a consolidated subsidiary)
- 4
Use of funds
- 5
Exclusive distribution agreement and future developments
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The Company will acquire 35% of REMED JAPAN’s voting rights and, in the second stage, is expected to exercise a call option during a specified period after finalization of the results for the fiscal year ending December 2028, increasing its voting interest to 51%.
This indicates whether the companies will do more than work together, such as holding each other’s shares or seconding personnel (capital and business alliance).
REMED JAPAN is expected to become an equity-method affiliate. The impact on the Company’s consolidated results has not been determined at this time, but is expected to be immaterial.
| Item | Details |
|---|---|
| Name of alliance partner | REMED JAPAN 株式会社, Remed Co., Ltd. |
| Alliance partner's business activities | Sales, import and export, repair and maintenance, rental and leasing, and other activities involving medical equipment and medical supplies / Research, development, manufacture and sale of non-invasive electromagnetic medical devices, including transcranial magnetic stimulators (TMS), neuromuscular magnetic stimulators (NMS) and extracorporeal shock wave therapy devices (ESWT), for applications including neurorehabilitation, chronic pain and aesthetics |
| Alliance partner's location | Chuo-ku, Tokyo / Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, South Korea |
| Alliance partner's capital | ¥72.5 million / KRW 3.06 billion (approximately ¥306 million) |
| Alliance partner's net sales | Fiscal year ended December 2025: ¥132.895 million / Fiscal year ended December 2025: KRW 24.505 billion (approximately ¥2.451 billion) |
| Alliance partner's operating income | Fiscal year ended December 2025: operating loss of ¥39.639 million / Fiscal year ended December 2025: operating profit of KRW 726 million (approximately ¥73 million) |
| Type of alliance | Capital and Business Alliance |
| Details of the alliance | Subscription for a third-party allotment (first stage: making REMED JAPAN an equity-method affiliate), Management Structure, Right to acquire additional shares (second stage: making REMED JAPAN a consolidated subsidiary), Use of funds, Exclusive distribution agreement and future developments |
| Number of shares acquired | 156,154 shares (35.0% voting rights ownership) |
| Acquisition price | ¥78,077,000 |
| Shareholding ratio | 0.0% → 35.0%(Not disclosed) |
| Dispatch of directors and officers | The Company and REMED JAPAN are each expected to nominate 2 directors, and the Company is expected to appoint an audit & supervisory board member. One director from each company is expected to be appointed as representative director. |
| Numerical targets under the alliance | The Company will acquire 35% of REMED JAPAN’s voting rights and, in the second stage, is expected to exercise a call option during a specified period after finalization of the results for the fiscal year ending December 2028, increasing its voting interest to 51%. |
| Shareholding Policy | While the Company holds shares in REMED JAPAN, the exclusive distribution agreement may not be terminated, nor may prices be changed, without the Company’s consent. No additional acquisition exceeding 51% is currently planned. |
| Date of board resolution | 17 November 2026 |
| Contract Date | Early December 2026 (予定) |
| Share Acquisition Date and Payment Date | Early December 2026 (予定) |
| Impact on Business Performance | REMED JAPAN is expected to become an equity-method affiliate. The impact on the Company’s consolidated results has not been determined at this time, but is expected to be immaterial. |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To expand product sales in Japan by linking REMED’s medical devices with the Company’s A-COMS customer network. In addition to operational cooperation between the two companies, the Company will strengthen the relationship and accelerate sales expansion through its capital participation.